tirzepatide landmark trial for masld SURPASS-CVOT results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic At a glance factsheet: Tirzepatide
Description
The first week I could already tell my appetite was getting less but my biggest love has been the reduction in food noise
Tirzepatide is a dual GIP/GLP1 receptor agonist gaining attention for its potential in weight management
Research from SURMOUNT trials showed significant weight loss results beginning to differentiate from lower doses at the 5.0 mg tier
Our lineup includes: Wegovy (Semaglutide Injection) : A weekly injection widely researched for weight management, allowing for potential weight loss of 15% over 68 weeks
Telehealth focuses on access and convenience while keeping communication private and HIPAA-conscious
All patients begin at 2.5 mg once weekly, regardless of whether theyre using it for weight loss or diabetes
